-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or… Read More..

-Gross Margin Increases 33% to $2.0 Million; Net Income Increases to $0.3 Million or $0.05 per share- -PBRT Revenue and Volume Increases 82% and 40% Respectively- -Conference Call Thursday November 10th at 3:00pm ET / 12:00pm PT- SAN FRANCISCO, CA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American… Read More..

KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DEM-A22-1 is expected to begin on November 15, 2022. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD")… Read More..